JUBILANT GENERICS
GenericsJUBILANT GENERICS is a generic drug manufacturer focused on Neurology, Cardiovascular, Gastroenterology.
JUBILANT GENERICS's Key Drugs
JUBILANT GENERICS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
JUBILANT GENERICS's Recent FDA Approvals
New NDA/BLA approvals for JUBILANT GENERICS over the last two years — novel drugs only, excluding generics and label supplements.
JUBILANT GENERICS's Therapeutic Areas
JUBILANT GENERICS's approved drugs and pipeline span 3 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
JUBILANT GENERICS's Top Competitors
JUBILANT GENERICS's closest competitors by therapeutic-area and drug-target overlap include VALIDUS PHARMS, QUAGEN, and WARNER CHILCOTT. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
JUBILANT GENERICS Pipeline Snapshot
Active clinical trials for JUBILANT GENERICS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (1)
Company Info
- First Approval
- 2011-02-28
- Latest
- 2026-08-17
- Applications
- 50